| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 529 | 2015 |
| Fis1 and Bap31 bridge the mitochondria–ER interface to establish a platform for apoptosis induction R Iwasawa, AL Mahul‐Mellier, C Datler, E Pazarentzos, S Grimm The EMBO journal 30 (3), 556-568, 2011 | 502 | 2011 |
| AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ... Cancer cell 27 (4), 533-546, 2015 | 309 | 2015 |
| RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer G Hrustanovic, V Olivas, E Pazarentzos, A Tulpule, S Asthana, ... Nature medicine 21 (9), 1038-1047, 2015 | 289 | 2015 |
| NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer CM Blakely, E Pazarentzos, V Olivas, S Asthana, JJ Yan, I Tan, ... Cell reports 11 (1), 98-110, 2015 | 216 | 2015 |
| Specific disintegration of complex II succinate: ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction A Lemarie, L Huc, E Pazarentzos, AL Mahul-Mellier, S Grimm Cell Death & Differentiation 18 (2), 338-349, 2011 | 120 | 2011 |
| Mitochondrial Ca2+ influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction MS Hwang, CT Schwall, E Pazarentzos, C Datler, NN Alder, S Grimm Cell Death & Differentiation 21 (11), 1733-1745, 2014 | 98 | 2014 |
| De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF AL Mahul-Mellier, E Pazarentzos, C Datler, R Iwasawa, G AbuAli, B Lin, ... Cell Death & Differentiation 19 (5), 891-899, 2012 | 75 | 2012 |
| Adaptive stress signaling in targeted cancer therapy resistance E Pazarentzos, TG Bivona Oncogene 34 (45), 5599-5606, 2015 | 69 | 2015 |
| Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation E Pazarentzos, P Giannikopoulos, G Hrustanovic, J St John, VR Olivas, ... Oncogene 35 (9), 1198-1205, 2016 | 44 | 2016 |
| Integrated systems and methods for automated processing and analysis of biological samples, clinical information processing and clinical trial matching T Matsuguchi, AF Caulin, JAS John, S Soi, EC Ahmed, E Pazarentzos, ... US Patent App. 15/727,491, 2018 | 38 | 2018 |
| Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution VD Jonsson, CM Blakely, L Lin, S Asthana, N Matni, V Olivas, ... Scientific reports 7 (1), 44206, 2017 | 38 | 2017 |
| IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF‐κB retention E Pazarentzos, AL Mahul‐Mellier, C Datler, W Chaisaklert, MS Hwang, ... The EMBO journal 33 (23), 2814-2828, 2014 | 36 | 2014 |
| CKMT1 regulates the mitochondrial permeability transition pore in a process that provides evidence for alternative forms of the complex C Datler, E Pazarentzos, AL Mahul-Mellier, W Chaisaklert, MS Hwang, ... Journal of cell science 127 (8), 1816-1828, 2014 | 34 | 2014 |
| De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1 AL Mahul-Mellier, C Datler, E Pazarentzos, B Lin, W Chaisaklert, G Abuali, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1823 (8), 1353-1365, 2012 | 29 | 2012 |
| Integrated systems and methods for automated processing and analysis of biological samples, clinical information processing and clinical trial matching T Matsuguchi, JAS John, E Pazarentzos, W Polkinghorn, ... US Patent App. 15/727,501, 2018 | 27 | 2018 |
| Dose-dependent neuroprotection of VEGF165 in Huntington's disease striatum SM Ellison, A Trabalza, V Tisato, E Pazarentzos, S Lee, V Papadaki, ... Molecular Therapy 21 (10), 1862-1875, 2013 | 25 | 2013 |
| The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro CP Watson, E Pazarentzos, M Fidanboylu, B Padilla, R Brown, ... Brain research 1648, 232-242, 2016 | 23 | 2016 |
| Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers N Chatterjee, E Pazarentzos, MK Mayekar, P Gui, DV Allegakoen, ... Cell reports 28 (9), 2317-2330. e8, 2019 | 18 | 2019 |
| The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis G AbuAli, W Chaisaklert, E Stelloo, E Pazarentzos, MS Hwang, D Qize, ... Oncogene 34 (13), 1718-1728, 2015 | 11 | 2015 |
Stefan GrimmProfessor of Toxicology, Imperial College LondonVerified email at imperial.ac.uk
